Lung Cancer Companies

AstraZeneca's Tagrisso shows promising results in a Phase III trial: This trial demonstrated Tagrisso's efficacy in treating EGFR-mutated non-small cell lung cancer (NSCLC) with less brain metastases compared to other targeted therapies.

Mirati Therapeutics' investigational drug adavosertib receives Breakthrough Therapy designation from the FDA: This designation recognizes the potential of adavosertib for treating KRAS G12C-mutated NSCLC, a previously difficult-to-treat mutation.

Roche acquires Blueprint Medicines for $3.9 billion: This acquisition strengthens Roche's lung cancer portfolio by adding Blueprint's expertise in targeted therapies for RET-driven cancers, including some lung cancers.

Merck & Co. partners with BeiGene to develop and commercialize tislelizumab: This collaboration expands access to tislelizumab, a promising PD-1 inhibitor, for treating lung cancer and other solid tumors worldwide.

• Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Switzerland)


• Pfizer (U.S.)


• Bristol-Myers Squibb (U.S.)


• Eli Lilly and Company (U.S.)


• Sanofi (France)